Attached files

file filename
10-K - FORM 10-K - Viracta Therapeutics, Inc.d10k.htm
EX-4.2 - SPECIMEN COMMON STOCK CERTIFICATE OF THE REGISTRANT - Viracta Therapeutics, Inc.dex42.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Viracta Therapeutics, Inc.dex231.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) OR 15D-14(A) - Viracta Therapeutics, Inc.dex311.htm
EX-10.49 - MASTER SERVICES AGREEMENT - AAI DEVELOPMENTAL SERVICES INC. - Viracta Therapeutics, Inc.dex1049.htm
EX-10.53 - MASTER SERVICES AGREEMENT - ALBANY MOLECULAR RESEARCH, INC. - Viracta Therapeutics, Inc.dex1053.htm
EX-10.54 - MASTER SERVICES AGREEMENT - ICON CLINICAL RESEARCH LIMITED - Viracta Therapeutics, Inc.dex1054.htm
EX-10.16 - WARRANT - Viracta Therapeutics, Inc.dex1016.htm
EX-10.50 - FIRST AMENDMENT TO MASTER SERVICES AGREEMENT - AAIPHARMA INC. - Viracta Therapeutics, Inc.dex1050.htm
EX-10.52 - THIRD AMENDMENT TO MASTER SERVICES AGREEMENT - AAIPHARMA SERVICES CORP - Viracta Therapeutics, Inc.dex1052.htm
EX-10.51 - SECOND AMENDMENT TO MASTER SERVICES AGREEMENT - AAIPHARMA INC. - Viracta Therapeutics, Inc.dex1051.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) OR 15D-14(A) - Viracta Therapeutics, Inc.dex312.htm

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to

18 U.S.C. Section 1350, as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Daniel N. Swisher, Jr., Chief Executive Officer of Sunesis Pharmaceuticals, Inc. (the “Company”), and Eric H. Bjerkholt, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

 

  1. The Company’s Annual Report on Form 10-K for the period ended December 31, 2010, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and

 

  2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned have set their hands hereto as of the 29th day of March, 2011.

 

/S/    DANIEL N. SWISHER, JR.             /S/    ERIC H. BJERKHOLT        
Daniel N. Swisher, Jr.     Eric H. Bjerkholt
Chief Executive Officer     Chief Financial Officer

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sunesis Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.